UNASSIGNED: Post-herpes simplex virus @entity198 relapses have been recently associated with @entity792 driven by autoantibodies against @entity3391 ( @entity3391 ) receptors. Because it offers different treatment options, determination of this condition is important. Between 2011 and 2014, 7 @entity1 with proven diagnosis of herpes simplex virus @entity198 were identified in a university hospital of Istanbul. Two @entity1 had neurologic relapse characterized mainly by @entity717 2 to 3 weeks after initial @entity198 . The first @entity1 received a second 14 days of @entity1033 treatment together with antiepileptic drugs and left with severe @entity16 . The second @entity1 was found to be @entity3391 receptors antibody positive in the cerebrospinal fluid. She was treated with intravenous immunoglobulin and @entity617 . She showed substantial improvement, gradually regaining lost neurologic abilities. Post-herpes simplex virus @entity198 relapses may frequently be immune-mediated rather than a viral reactivation, particularly in @entity1 displaying @entity717 like @entity8684 . Immunotherapy may provide benefit for this potentially devastating condition, like the case described in this report.

Role of Autoantibodies to @entity3391 ( XXXX ) Receptor in Relapsing Herpes Simplex @entity198 : A Retrospective, One-Center Experience.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity1033 :: ('MESH:D000212', 'Chemical') :: ['acyclovir'] @entity198 :: ('MESH:D004660', 'Disease') :: ['encephalitis'] @entity3391 :: ('D016202', 'Chemical') :: ['NMDA', 'N-methyl-d-aspartate'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic sequelae'] @entity8684 :: ('MESH:D001264', 'Disease') :: ['choreoathetosis'] @entity717 :: ('MESH:D009069', 'Disease') :: ['movement disorders'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmunity'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']
@entity3391 :: (D016202,Chemical) :: ['NMDA']
